Naurex Raises $38M Series B Following Promising Phase II Trial
December 18, 2012
Naurex, a clinical-stage developer of psychiatric and neurological treatments, has raised $38 million in a Series B round led by new investor Baxter International. Another new investor, Savitr Capital, participated in the round as well, with numerous existing investors also contributing. In early December, Naurex reported promising Phase II results for its antidepressant GLYX-13. The company plans to use the new capital for a Phase IIb trial of GLYX-13, as well as clinical trials of the second-generation oral product NRX-1074 and continued development of center nervous system (CNS) programs.